NCT03251027Active, not recruiting
Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma
Intensity-Modulated Stereotactic Radiotherapy as an Upfront Scalp-Sparing Intervention for the Treatment of Newly Diagnosed Grade II-IV Gliomas
Source: ClinicalTrials.gov · Last updated 27 Jan 2026
Brief summary (registry, in English)
This phase II trial studies how well intensity-modulated stereotactic radiation therapy works in treating patients with grade II-IV glioma. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 14 Aug 2017
- Start date
- 17 Jul 2017
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Diseases
- Glioblastoma
- NCT number
- NCT03251027
What you commit to
- Study type: Interventional
- Participants enrolled: 100
- From 17 Jul 2017 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior history of scalp radiation or intolerance to standard course of radiation treatment
Other illness
- Co-morbidities that would influence wound healing including diabetes (insulin dependent) or smoking (current ongoing use)
- Active collagen vascular disease
Other
- Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
- Karnofsky performance status (KPS) \< 60
- Patient can't have magnetic resonance imaging (MRI) scan
Who the study is looking for
- Patients must have histologically confirmed low or high grade glioma (grade II-IV)
- Karnofsky performance status (KPS) \>= 60
- Patients must have recovered from the effects of surgery; there must be a minimum of 21 days from the day of surgery to the day of protocol treatment
- Estimated survival \>= 3 months
- Labs considered acceptable per standard of care
- Patient must sign a study specific informed consent form
- Radiation treatment must begin \>= 3 weeks and =\< 8 weeks after surgery
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sidney Kimmel Cancer Center at Thomas Jefferson University Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.